Pre-made Mapatumumab benchmark antibody (Whole mAb, anti-TNFRSF10A/TRAIL-R1 therapeutic antibody, Anti-APO2/CD261/DR4/TRAILR-1/TRAILR1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-TNFRSF10A/TRAIL-R1 therapeutic antibody (Pre-made Mapatumumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer.[1] It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types.[2]
| Products Name (INN Index) | Pre-Made Mapatumumab Biosimilar, Whole Mab, Anti-TNFRSF10A/TRAIL-R1 Antibody: Anti-APO2/CD261/DR4/TRAILR-1/TRAILR1 therapeutic antibody |
|---|---|
| INN Name | mapatumumab |
| Target | TNFRSF10A |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Cambridge?Antibody Technology (Cambridge UK) / Human?Genome Sciences?Inc. (HGSI) (Rockville MD USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Cambridge Antibody Technology (CAT) human antibody phage display library |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF10A |
| Package |
